Alpha proteinase inhibitor (human)

(Prolastin-C®)

Prolastin-C®

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 500 mg [10 mL], 1,000 mg [20 mL], 4,000 mg [80 mL])
Drug ClassAlpha1 proteinase inhibitors (human)
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitripsin deficiency).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Alpha proteinase inhibitor (human) (Prolastin-C) is employed for chronic augmentation and maintenance therapy in adults displaying clinical evidence of emphysema due to severe hereditary deficiency of Alpha1-PI, also known as alpha1-antitrypsin deficiency.
  • Information regarding this drug was derived from a study that reviews the diagnosis and treatment of AATD-related lung disease, particularly in the context of Australia and New Zealand.
  • There is no direct comparison between Prolastin-C and other therapies regarding safety or effectiveness provided in the study. It instead focuses on broader aspects related to alpha1 antitrypsin augmentation therapy, which includes intravenous infusions of exogenous AAT protein.
  • The importance of tailored treatments for those with AATD-related lung disease has been emphasized. These include testing for AATD, monitoring disease progression, addressing conditions in heterozygous patients, and exploring various therapeutic options, including surgical interventions for severe cases.
  • Broader considerations such as genetic counseling, involvement in patient support groups, monitoring of liver diseases, and the establishment of national registries specifically targeting individuals suffering from ATTD in the Australia and New Zealand region are mentioned.
  • Detailed comparative data on safety or effectiveness comparisons among different subgroups using Prolastin-C relative to other treatments were not available based on this study.

Product Monograph / Prescribing Information

Document TitleYearSource
Prolastin-C Liquid (alpha-1 proteinase inhibitor) Prescribing Information.2020Grifols Therapeutics., Research Triangle Park, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. 2017International Journal of Chronic Obstructive Pulmonary Disease

Clinical Practice Guidelines